--- title: Novel Biomarkers and Surrogate Endpoints Clarify Sickle Cell Disease Status and the Effects of Disease Modifying Therapies description: "FSCDR\nSickle Cell Disease\nBiomarkers" image: https://www.functionalfluidics.com/hubfs/Screenshot%202019-06-06%2017.05.39.png --- [![functionalfluidics_logo](https://www.functionalfluidics.com/hs-fs/hubfs/functionalfluidics_logo.jpg?width=132&name=functionalfluidics_logo.jpg)](https://www.functionalfluidics.com/) - [About Us](https://www.functionalfluidics.com/about-us) - [Services](https://www.functionalfluidics.com/services) - [Assays](https://www.functionalfluidics.com/assays-2) - [Flow Adhesion](https://www.functionalfluidics.com/assays/flow-adhesion) - [Mechanical Fragility](https://www.functionalfluidics.com/assays/mechanical-fragility) - [Dynamic Sickling Assay](https://www.functionalfluidics.com/assays-dynamicsicklingassay) - [Oxygenscan](https://www.functionalfluidics.com/assays/lorrca-oxygenscan) - [Osmoscan](https://www.functionalfluidics.com/assays-2/flow-adhesion-reverse-0) - [Contract Research](https://www.functionalfluidics.com/contractresearch) - [Nigeria Research Center](https://www.functionalfluidics.com/functional_fluidics_nigeria) - [RBC Test Menu](https://www.functionalfluidics.com/hubfs/Test%20Menu%20(2).pdf) - Scientific Resources - [Peer Reviewed Publications](https://www.functionalfluidics.com/scientificresources/peerreviewed) - [Abstracts](https://www.functionalfluidics.com/scientificresources/abstracts) - [ELIPSIS](https://www.functionalfluidics.com/scientificresources/elipsis) - [News](https://www.functionalfluidics.com/news-and-presentations) [< Go Back To News & Media](https://www-functionalfluidics-com.sandbox.hs-sites.com/news-and-presentations/) ## Novel Biomarkers and Surrogate Endpoints Clarify Sickle Cell Disease Status and the Effects of Disease Modifying Therapies Novel Biomarkers and Surrogate Endpoints Clarify Sickle Cell Disease Status and the Effects of Disease Modifying Therapies - - - June 7, 2019 0% read Subscribe to our Newsletter     **We will have an exhibit in the Caribbean Ballroom **please stop by to see us! We will be leading an educational seminar Saturday 3:30-5:30: **Novel Biomarkers and Surrogate Endpoints Clarify Sickle Cell Disease Status and the Effects of Disease Modifying Therapies** [https://sched.co/NRdQ](https://sched.co/NRdQ?utm_source=hs_email&utm_medium=email&_hsenc=p2ANqtz-_wLv-jYkJ3c-MFCz8zKkIxxE-TZ-3t46WI8hhW3FOC6XNohpIt7T_SBNnZxEljWX3VVm8D) The clinical pain and fatigue characteristic of sickle cell disease is difficult to objectively quantify.  Clinicians cannot depend on their physical exam, imaging studies, or laboratory data to validate claims of pain by their patients.  This challenge often creates physician and patient dissatisfaction, and makes it difficult to assess individual patient response to SCD modifying therapy in clinical trials. Biomarkers associated with cellular adhesion, inflammation, coagulation, anemia/hemolysis, cellular aggregates, microparticles and nitric oxide metabolism may help to objectively assess patient-reported outcomes (PROs) and response to disease modifying therapy.  There is an urgent need for validated biomarkers in sickle cell disease that facilitate open communication between the healthcare team, industry, and individuals with SCD.  We will highlight the current “state of the art” in the application of biomarkers and surrogate endpoints as applied to SCD in this educational session. Presenters: Patrick Hines, MD/PhD Associate Professor of Pediatric Critical Care Medicine Children’s Hospital of Michigan Research Associate, Department of Physiology, WSU School of Medicine Functional Fluidics, Founder and CEO Industry Perspective on Biomarkers and Surrogate Endpoints in SCD Clinical Trials Kenneth R. Bridges, MD Vice President of Medical Affairs Global Blood Therapeutics  Industry Perspective on Biomarkers and Surrogate Endpoints in Clinical Practice Charles Stark, PharmD Senior Vice President of Research and Development Emmaus Life Sciences, Inc **We will be presenting an Abstract on Sunday from 3:30-5:00** 3. JSCDH-D-19-00036 "Development and Evaluation of a Sickle Cell Disease Severity Index to Validate Clinical Adhesion Biomarkers" Corresponding author:  Jennell White, PhD [https://sched.co/LVKm](https://sched.co/LVKm?utm_source=hs_email&utm_medium=email&_hsenc=p2ANqtz-_wLv-jYkJ3c-MFCz8zKkIxxE-TZ-3t46WI8hhW3FOC6XNohpIt7T_SBNnZxEljWX3VVm8D) Subscribe to our Newsletter Subscribe to our Newsletter ### ### Recommended Reads ![](https://www.functionalfluidics.com/hubfs/Screenshot%202025-12-01%20105529.png) Dec 1, 2025 #### [Functional Fluidics Welcomes Biopharma Leader Bert Bruce as Senior Advisor](https://www.functionalfluidics.com/publications/functional-fluidics-welcomes-biopharma-leader-bert-bruce-as-senior-advisor) ![](https://www.functionalfluidics.com/hubfs/Screenshot%202025-11-30%20195918.png) Dec 1, 2025 #### [Functional Fluidics to Present New Sickle Cell Disease Data at the 2025 ASH Annual Meeting in Orlando, Florida](https://www.functionalfluidics.com/publications/functional-fluidics-to-present-new-sickle-cell-disease-data-at-the-2025-ash-annual-meeting-in-orlando-florida) ### Contact Us   # **Our Location** 440 Burroughs Street, Suite 447, Detroit, MI 48202 United States Email: [info@functionalfluidics.com](mailto:info@functionalfluidics.com) Phone:313-315-2555 ### Subscribe to Our Newsletter - [Services](https://www.functionalfluidics.com/services) - [Assays](https://www.functionalfluidics.com/assays-2) - [RBC Test Menu](https://www.functionalfluidics.com/hubfs/Test%20Menu%20(2).pdf) - [Publications](https://www.functionalfluidics.com/publications/tag/publications) © Copyright Functional Fluidics 2016.